TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01108146
Drug: Arm 1 Hydrocortisone 10 mg
Normalized name: hydrocortisone 1 MG/MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group 1: Administration of Hydrocortisone and/or Placebo in the following order:~1 week placebo- 1 week 10 mg hydrocortisone - 1 week placebo - 1 week 30 mg hydrocortisone
Study: NCT01108146
Drug: Arm 2 Hydrocortisone 30 mg
Normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Drug: Hydrocortisone 30 mg~Group 2: Administration of Hydrocortisone and/or Placebo in the following order:~1 week hydrocortisone 30 mg/d- 1 week placebo - 1 week hydrocortisone 10 mg/d - 1 week placebo
Study: NCT00202722
Drug: Remifentanil
Normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous patient controlled analgesia (ivpca) during labour
Study: NCT02025907
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: One placebo capsule taken orally (by mouth) once daily.
Study: NCT00356928
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 50 mg/kg/day intravenously (IV) on Days -2 and -1.
Study: NCT02651584
Drug: CAM2038 SC injection
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02651584
Drug: SL BPN/NX tabs
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02651584
Drug: placebo SC injections
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02651584
Drug: SL placebo tablets
Normalized name: placebo Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00593463
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (sugar pill or microcrystalline cellulose): oral capsule may possibly be given
Study: NCT01275469
Drug: GFT505 80mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hard gelatin capsules dosed at 20mg, oral administration, 4 capsules per day before breakfast.
Study: NCT01275469
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hard gelatin capsules, oral administration, 4 capsules per day before breakfast.
Study: NCT02826642
Drug: IDH305
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02725723
Drug: epidural injection
Normalized name: Sufentanil Citrate 50 ug in 1 mL EPIDURAL INJECTION
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00177333
Drug: Doxycycline
Normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00769184
Drug: Corticosteroid
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: One side of body:~clobetasol: 2 applications / day along with LCD application 2 applications/day
Study: NCT00769184
Drug: LCD
Normalized name: MGlcDAG (1->2) glucosyltransferase
Approvals — FDA: no, EMA: no, PMDA: no
Description: One side of body:~LCD Solution: 2 applications / day along with clobetasol 2 applications/day
Study: NCT04481815
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 3.5g/m2 intravenous infusion for 4 hours in d1, every 21 days for 1 cycle, 6 cycles will be prescribed.
Study: NCT04001621
Drug: Pyrotinib combined with capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: pyrotinib 400 mg once daily; Capecitabine 1000 mg/m2 per day on day 1 through 14, every 21 days.
Study: NCT01776515
Drug: Tramadol hydrochloride/Acetaminophen Tab.
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01776515
Drug: Tramadol hydrochloride/Acetaminophen SR Tab.
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02445807
Drug: DFD06-Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice daily topical application for 14 days.
Study: NCT03821155
Drug: Corticosteroid
Normalized name: CORTICOSTEROIDS
DrugBank: Corticosterone (DB04652)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisolone
Study: NCT02445807
Drug: Vehicle Cream
Normalized name: vehicle cream base no.160
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice daily topical application for 14 days.
Study: NCT04304716
Drug: Regional Anesthesia
Normalized name: ACL6SP45 REGIONAL ANESTHESIA KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Block performed is an indwelling wound bed or popliteal catheter placed intraoperatively
Study: NCT01825707
Drug: [14C]-YH4808 200 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: \[14C\]-YH4808 200 mg (oral) on day1
Study: NCT02424253
Drug: ZPL-3893787
Approvals — FDA: no, EMA: no, PMDA: no
Description: ZPL-3893787
Study: NCT02424253
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matched Placebo
Study: NCT01897454
Drug: Fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT01897454
Drug: Leucovorin Calcium
Normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT03179332
Drug: Fiasp®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single subcutaneous administration of a bolus of 0.15 U/kg body with a pump
Study: NCT03179332
Drug: Novorapid®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single subcutaneous administration of a bolus of 0.15 U/kg body with a pump
Study: NCT00094978
Drug: Depsipeptide
Normalized name: palmitoyl dipeptide-7
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02598661
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imetelstat sodium-matching placebo IV infusion.
Study: NCT01972490
Drug: mFOLFOX6
Approvals — FDA: no, EMA: no, PMDA: no
Description: mFOLFOX-6 (oxaliplatin, 85mg/m2 on day 1 infused during 2 hours;LV400mg/m2 on days 1 infused during 2 hours, followed by FU 400 mg/m2 intravenous bolus then 2400 mg/m2 continuous infusion for 46 hours)
Study: NCT01839279
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04430985
Drug: Leucovorin
Normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Day 1 each cycle: 400 mg/m2 i.v.
Study: NCT00573417
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT05256147
Drug: Ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Patient will receive ibuprofen 400 mg before the phototherapy session.
Study: NCT02502578
Drug: CNT-01 500 mg capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: After being informed about the study and potential risks, all patients giving written informed consent undergo screening tests to determine eligibility for study enrollment. On Day 1, patients who meet the eligibility criteria will start taking CNT-01 500mg orally three times daily for 14 days. On Day 15, patients will take CNT-01 500 mg only once after blood drawing.
Study: NCT02788240
Drug: Peg GCSF
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02788240
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02195583
Drug: Sodium fluoride (1426 ppm) + zinc base A
Normalized name: sodium fluoride Oral Solution [Fluor a Day]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zinc base A, 1426ppm fluoride as sodium fluoride in a silica gel base
Study: NCT03045562
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will be assigned to receive 100ml of normal saline in catherter room setting,and following similar medicine once daily for 7 days.
Study: NCT02195583
Drug: Sodium fluoride (1426 ppm) + zinc base B
Normalized name: Sodium Fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Zinc base B, 1426ppm fluoride as sodium fluoride in a silica gel base
Study: NCT04289532
Drug: 99mTc-RWY
Approvals — FDA: no, EMA: no, PMDA: no
Description: 99mTc-RWY were injected into volunteers and patients before the SPECT/CT scans .
Study: NCT00231829
Drug: Celecoxib
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01783561
Drug: Caffeine
Normalized name: Caffeine
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Infants will receive a blinded dose of either placebo (IV normal saline) or IV caffeine citrate 20mg/kg infused over 10 minutes within the first 2 hours of life. They will receive a blinded dose of the opposite of what they received in the DR (placebo or caffeine) at 6 hours of life. Therefore, the intervention is timing of initial caffeine dose.
Study: NCT01367535
Drug: SC Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03872128
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo
Study: NCT00840073
Drug: Mavik® 4 mg Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 x 4 mg, single-dose fed
Study: NCT02648438
Drug: AZD7594 Oral suspension (1200 μg oral formulation)
Normalized name: Guiadrine G-1200 Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1 - 10 mg/g oral solution; AZD7594 1200 μg oral
Study: NCT02648438
Drug: AZD7594 Inhalation powder (400 μg) by DPI Device 1 (monodose inhaler)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhalation powder, hard capsules 400 μg Monodose inhaler; AZD7594 400 μg by dry powder inhaler (DPI) Device 1 (Monodose inhaler)
Study: NCT02648438
Drug: AZD7594 Inhalation powder (400 μg) by DPI device 2 (multiple-dose inhaler)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhalation powder, multiple-dose dry powder inhaler (DPI) 400 μg; AZD7594 400 μg by DPI Device 2 (multiple-dose DPI)
Study: NCT02648438
Drug: AZD7594 Pressurized inhalation suspension (400 μg) by pMDI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhalation suspension 200 μg; AZD7594 400 μg by pressurized metered-dose inhaler (pMDI); 2 puffs x 200 μg = 400 μg
Study: NCT02210195
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo daily for 8 weeks.
Study: NCT00917150
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral administration of placebo, once daily for 24months
Study: NCT02074020
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered via subcutaneous injection once per week
Study: NCT01372345
Drug: CIPRO®XR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciprofloxacin 1000 mg Tablets Dr. Reddy's Laboratories Limited
Study: NCT00554502
Drug: supportive therapy with: ACE-inhibitor / ARB / Statin
Approvals — FDA: no, EMA: no, PMDA: no
Description: * Antihypertensive therapy with a target blood pressure below 125/75 mmHg (following current clinical guidelines).~* ACE-inhibitors (ARB when an ACE-inhibitor is not tolerated)~* Other antihypertensive medications depending on the clinical decision and following current guidelines.~* Statin therapy~* Dietary counseling for a low-sodium diet and, if GFR is below 60 ml/min, for a protein intake of 0.8 g/kg/day.
Study: NCT02491905
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00554502
Drug: supportive and immunosuppressive therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: * supportive therapy as outlined above~* depending on GFR:~  * methylprednisolone and prednisolone~ * cyclophosphamide and prednisolone; after 3 months azathioprine with prednisolone~* Concomitant medication with the immunosuppressive treatment following current clinical practice
Study: NCT02302976
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01422109
Drug: YH14659
Approvals — FDA: no, EMA: no, PMDA: no
Description: YH14659 capsule by oral
Study: NCT03278470
Drug: HL237
Normalized name: Hydrocodone/Levorphanol 237
Approvals — FDA: no, EMA: no, PMDA: no
Description: Experimental
Study: NCT03278470
Drug: Placebo Oral Tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo with same properties except for active ingredient
Study: NCT03708458
Drug: indomethacin suppository
Normalized name: indomethacin Rectal Suppository
Approvals — FDA: no, EMA: no, PMDA: no
Description: the investigators aimed to perform a comparative study, evaluating the efficacy of three prophylactic approaches aiming to reduce the risk of PEP, using indomethacin and/or N-acetylcysteine -NAC, in different regimens
Study: NCT04391595
Drug: LY3214996
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg of LY3214996 daily for 6 doses over 5.5 days prior to surgical resection. Participants with tumors demonstrating PK-response in Phase 0 will continue treatment with recommended Phase 2 dose (RP2D) continuously in 21d cycles after surgery.
Study: NCT03206008
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT02045472
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00644774
Drug: azithromycin
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 2.5 ml of cherry flavored oral suspension 100 mg/5 ml
Study: NCT01709513
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo for alirocumab, ezitimibe and atorvastatin.
Study: NCT04442945
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral placebo
Study: NCT02268903
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo in one single direct intra venous injection
Study: NCT03970447
Drug: VT1021
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dosage Form: Infusion for intravenous administration Strength: 10 mg/mL Standard Regimen Newly Diagnosed: Dose as confirmed through the dose finding phase, administered twice weekly (Mon and Thurs or Tues and Fri or Mon and Fri).~Standard Regimen Recurrent: 12 mg/kg administered twice weekly (Mon and Thurs or Tues and Fri or Mon and Fri). The drug is available as a sterile solution of the acetate salt formulated with phosphate-buffered saline, mannitol, and 2.5% polysorbate 80. The required volume stock solution for the patient is calculated. The corresponding volume is diluted in 500 mL of either 0.9% saline or D5W, prior to intravenous administration.
Study: NCT02575950
Drug: LEO43204
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02575950
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04574583
Drug: M7824
Normalized name: M7824
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive M7824 at a flat dose of 1,200 mg intravenously on Days 1 and 15 of each cycle.
Study: NCT03686033
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive E2082-matched placebo tablets orally.
Study: NCT01045161
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose-matched placebo, oral inhalation twice per day for 12 weeks. At week 12, patients who were on placebo will receive open label 400 µg aclidinium bromide for 40 weeks of treatment
Study: NCT01911676
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00102973
Drug: Doxorubicin HCl Liposome Injection
Normalized name: DOXORUBICIN HYDROCHLORIDE LIPOSOME
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Active Comparator
Study: NCT01970371
Drug: tigecycline
Normalized name: Tigecycline
DrugBank: Tigecycline (DB00560)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01970371
Drug: antibiotic of Investigator's choice
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02442128
Drug: propofol /Fentanyl
Approvals — FDA: no, EMA: no, PMDA: no
Description: fentanyl 2 μg/kg and propofol 2 mg/kg Both test drugs will be made up to 10 ml with saline. fentanyl will be first administered intravenously over 30 s followed by propofol over 20 s.
Study: NCT02442128
Drug: Fentanyl / propofol
Approvals — FDA: no, EMA: no, PMDA: no
Description: fentanyl 2 μg/kg and propofol 3 mg/kg. Both test drugs will be made up to 10 ml with saline. fentanyl will be first administered intravenously over 30 s followed by propofol over 20 s.
Study: NCT00870441
Drug: ASP2151
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral
Study: NCT00870441
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral
Study: NCT03797014
Drug: B/F/TAF
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed dose combination B/F/TAF (50 mg/ 200 mg/ 25 mg/ tablet) administered orally once daily without regards to food.
Study: NCT01433575
Drug: RO4917838
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg single oral dose
Study: NCT01433575
Drug: RO4917838
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg single oral dose
Study: NCT00424424
Drug: MK0719
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04458298
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo infusion will be administered intravenously.
Study: NCT01001403
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 ml of normal saline
Study: NCT03994172
Drug: placebo tablet
Normalized name: placebo Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: The placebo tablet in the trial will be purchased from Consolidated Midland Corporation in Brewster, NY. Each white tablet contains Lactose, Stearic Acid and Magnesium Stearate (330 mg total). Subjects randomized to the placebo arm or Placebo - Arm #2 - will take one tablet orally at the same time as he injects the teriparatide each day. Placebo tablets will be given only once daily but given every single day of the trial starting with the Randomization Visit for the duration of 48 weeks or 11 months of the trial.
Study: NCT03715881
Drug: Oral prednisolone administration 50 mg
Normalized name: prednisolone Oral Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg oral prednisolone from the onset of the disease for 1 week, with the dose gradually reduced within 2 weeks and then discontinued
Study: NCT00844753
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo + parent management treatment
Study: NCT02142777
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The placebo has no active ingredients but is made to look like the study drug.
Study: NCT01950000
Drug: Fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02446431
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide is an alkylating agent related to nitrogen mustard and is inactive until it is metabolized by P450 isoenzymes (CYP2B6, CYP2C9, and CYP3A4) in the liver to active compounds. The initial product is 4-hydroxycyclophosphamide (4-HC) which is in equilibrium with aldophosphamide which spontaneously releases acrolein to produce phosphoramide mustard. Phosphoramide mustard has been shown to produce interstrand DNA cross-link analogous to those produced by mechlorethamine. The plasma half-life ranges from 4.1 to 16 hours after IV administration. Cytoxan is taken orally as a 25 mg/m2 tablet daily for 14 days for 10 cycles (max dose =50mg). This totals 140 days over a 1.12 year period.
Study: NCT01348269
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: NaCl Solution
Study: NCT01468272
Drug: CHF 1535 50/6 NEXT DPI
Approvals — FDA: no, EMA: no, PMDA: no
Description: four inhalations of CHF 1535 50/6 NEXT DPI, a fixed combination of beclomethasone dipropionate 50 ug plus formoterol fumarate 6 ug (TOTAL DOSE:BDP/FF 200/24 ug)
Study: NCT03332485
Drug: ECP Colon Prep Kit
Normalized name: Sus scrofa colon preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: ECP Colon Prep Kit
Study: NCT03332485
Drug: MoviPrep®
Approvals — FDA: no, EMA: no, PMDA: no
Description: MoviPrep®
Study: NCT01553981
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Shape , size, color and odor matched Tab. of inert material every other day for 6 months
Study: NCT04155671
Drug: POF
Normalized name: Ta-Poff
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paclitaxel plus Oxaliplatin plus Leucovorin plus 5-FU
Study: NCT04155671
Drug: FOLFOX plus PAC(ip)
Approvals — FDA: no, EMA: no, PMDA: no
Description: FOLFOX plus intraperitoneally paclitaxel
Study: NCT05512546
Drug: Aspir-Low Pill
Normalized name: Aspir-Low Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: patients were prescribed 75 mg/day of either aspirin
Study: NCT02300701
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT03381716
Drug: drug
Normalized name: Drug vehicle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Application bracket
Study: NCT01439555
Drug: Simvastatin
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Simvastatin, 40 mg per day orally
Study: NCT00376870
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo 30 mg/d
Study: NCT02781909
Drug: Ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Non-Steroid Anti-Inflammatory drug to be administered as adjunctive therapy
Study: NCT00085956
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03784079
Drug: GSK3640254
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK3640254 will be available with dosing strengths of 5 mg, 20 mg, and 100 mg to be administered as an oral capsule along with 240 mL of water.
Study: NCT03729674
Drug: Biosimilar
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biologic-naïve patients starting any biosimilar; patients switching to biosimilar from an alternative biologic therapy; or patients switching to a biosimilar after successfully completing and exiting a previous course of therapy with the equivalent originator drug.
Study: NCT03729674
Drug: Originator (legacy) drug
Normalized name: Legacy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biologic-naïve patients starting any originator (legacy) drug; patients switching to an originator drug from an alternative biologic therapy; or patients starting a new cycle with the originator drug.
Study: NCT00075023
Drug: Placebo Gel
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00176605
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 50 mg per day of cyclophosphamide orally for 21 consecutive days. Cyclophosphamide will be alternated with oral etoposide. The drug is taken 2 hours after breakfast. The patient will be asked to increase hydration throughout the day. Recommendation is at least 6, 8oz glasses of water or other non-caffeinated beverage. Week 4 of the each cycle will begin with cylcophosphamide. Chronic administration of cyclophosphamide at this dose has been well tolerated
Study: NCT01321710
Drug: Acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 51-90mg depending on infant weight (12.5mg per kg infant weight). Administered 30 minutes prior to immunization and q4-6h for a total of 5 doses.